Xtx Topco LTD Gossamer Bio, Inc. Transaction History

Xtx Topco LTD

$1.13 Billion
Q4 2024

A detailed history of Xtx Topco LTD transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 21,339 shares of GOSS stock, worth $29,874. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,339

Holding current value

$29,874

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$0.66 - $1.07 $14,083 - $22,832	21,339 New	21,339 $19,000
Q4 2023 Feb 13, 2024	BUY	$0.48 - $1.08 $25,659 - $57,734	53,458 New	53,458 $48,000
Q2 2023 Aug 14, 2023	SELL	$0.98 - $1.53 $383,528 - $598,774	-391,356 Reduced 90.34%	41,837 $50,000
Q1 2023 May 12, 2023	BUY	$0.96 - $2.92 $159,416 - $484,892	166,059 Added 62.16%	433,193 $545,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $12.87 $436,164 - $3.23 Million	250,669 Added 1522.44%	267,134 $579,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $14.88 $118,712 - $244,999	16,465 New	16,465 $197,000
Q1 2022 May 13, 2022	SELL	$8.44 - $12.49 $112,336 - $166,241	-13,310 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$10.12 - $14.07 $134,697 - $187,271	13,310 New	13,310 $151,000

Others Institutions Holding GOSS

# of Institutions

116

Shares Held

163M

Call Options Held

821K

Put Options Held

557K

Octagon Capital Advisors LP New York, NY

18.4M
Shares

$25.7 Million
3.68% of portfolio
Nea Management Company, LLC Timonium, MD

18.1M
Shares

$25.3 Million
1.16% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$14 Million
0.0% of portfolio
Alyeska Investment Group, L.P. Chicago, IL

8.81M
Shares

$12.3 Million
0.03% of portfolio
Arch Venture Management, LLC Chicago, IL

8.06M
Shares

$11.3 Million
4.56% of portfolio

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $132M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account